B&K Corp eyes IPO to keep its slow-developing drugs alive
The company focuses on wound-healing PDGF drugs and its core product, Pro-101-2, isn’t expected to enter Phase 3 clinical trials for at least three more years Key Takeaways: B&K lost…
PODCAST: A New EU Probe, and a Used Car IPO
The EU has launched a new probe after European firms complained of restricted access to China's huge medical equipment procurement market. Is the EU getting more aggressive on China's trade practices? And used car specialist Autostreets applies for a Hong Kong listing, touting a coming boom in Chinese used car sales. Why have Chinese traditionally preferred new cars, and what's changed now, if anything?
Bayzed joins IPO quest as medical rivalry heats up
The cancer treatment specialist is seeking a Hong Kong listing to fund its campaign in the M&A battle for China’s private healthcare market Key Takeaways: Over the past three years, Bayzed…
China-focused Tigermed staves off biopharma gloom
Investors have not been deterred by an earnings slide, wagering that the drugs services company is better placed to weather an industry storm than some biopharma stocks Key Takeaways: Tigermed…
Sunho Biologics gets green light for downsized IPO
The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…
New Horizon Health launches probe into disputed sales figures
The provider of cancer-screening products issued a positive profit alert in January, but the full earnings report has yet to appear after auditors raised questions about the company’s revenues Key…
BenQ files for IPO as business looks stable, but with few growth spots
China’s biggest private for-profit hospital operator plans to use funds from its planned listing to expand and upgrade its facilities Key Takeaways: BenQ Hospital has filed to list in Hong…
Recent Articles
RELATED ARTICLES
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US -
Kintor shares plunge after hair-loss drug flops in clinical trials
9939.HK
- InSilico seeks IPO boost to get AI drugs over the line
- HighTide Therapeutics places big IPO bet on “affluenza” drug
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
With no cure in sight, drugs firm LianBio begins exit strategy
LIAN.US
